Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...

A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...

Sanofi’s PERSEUS phase 3 study of tolebrutinib in primary progressive multiple sclerosis fails to meet primary endpoint: Paris Tuesday, December 16, 2025, 11:00 Hrs [IST] Sanofi ...

Sanofi provides update on tolebrutinib in primary progressive multiple sclerosisPERSEUS phase 3 study in primary progressive multiple sclerosis ...

Sanofi SA reported more hitches in the development of Bruton’s tyrosine kinase inhibitor tolebrutinib, saying the phase III Perseus study failed to meet its primary endpoint in primary progressive ...

Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t ...

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...

Results from the PERSEUS Phase III study showed that tolebrutinib did not meet its primary endpoint in delaying time to ...

Tolebrutinib received provisional approval in the United Arab Emirates in July 2025 for non-relapsing secondary progressive ...

Tolebrutinib was one of three oral BTK inhibitors that Sanofi acquired as part of its $3.7 billion buyout of Principia ...

Sanofi shares slide after FDA delays review of its MS drug tolebrutinib and a late-stage trial fails to meet its main goal.

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the ...